512 related articles for article (PubMed ID: 2878007)
1. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
[TBL] [Abstract][Full Text] [Related]
2. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion.
Barkan AL; Beitins IZ; Kelch RP
J Clin Endocrinol Metab; 1988 Jul; 67(1):69-73. PubMed ID: 2897974
[TBL] [Abstract][Full Text] [Related]
3. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E
J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
[TBL] [Abstract][Full Text] [Related]
4. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ
J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
[TBL] [Abstract][Full Text] [Related]
5. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
Lamberts SW; Uitterlinden P; del Pozo E
J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
[TBL] [Abstract][Full Text] [Related]
6. Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine.
Chiodini PG; Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG
J Clin Endocrinol Metab; 1985 Jan; 60(1):48-52. PubMed ID: 3917270
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatomedin-C measurement in acromegaly.
Losa M; Oeckler R; Schopohl J; Müller OA; Alba-Lopez J; von Werder K
J Neurosurg; 1989 Apr; 70(4):561-7. PubMed ID: 2647918
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
9. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly.
Shibasaki T; Hotta M; Masuda A; Imaki T; Obara N; Hizuka N; Takano K; Wakabayashi I; Demura H; Ling N
J Clin Endocrinol Metab; 1986 Jul; 63(1):167-73. PubMed ID: 2872226
[TBL] [Abstract][Full Text] [Related]
10. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
Lamberts SW; Zweens M; Verschoor L; del Pozo E
J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the criteria for assessing the outcome of treatment in acromegaly.
Lindholm J; Giwercman B; Giwercman A; Astrup J; Bjerre P; Skakkebaek NE
Clin Endocrinol (Oxf); 1987 Nov; 27(5):553-62. PubMed ID: 3450453
[TBL] [Abstract][Full Text] [Related]
12. Serum type III procollagen propeptide levels in acromegalic patients.
Verde GG; Santi I; Chiodini P; Cozzi R; Dallabonzana D; Oppizzi G; Liuzzi A
J Clin Endocrinol Metab; 1986 Dec; 63(6):1406-10. PubMed ID: 2878008
[TBL] [Abstract][Full Text] [Related]
13. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly.
Arafah BM; Rosenzweig JL; Fenstermaker R; Salazar R; McBride CE; Selman W
J Lab Clin Med; 1987 Mar; 109(3):346-54. PubMed ID: 3102658
[TBL] [Abstract][Full Text] [Related]
14. Somatomedin-C in active and successfully treated acromegaly.
Knappe G; Hesse V; Jahreis G; Rohde W; Gerl H
Exp Clin Endocrinol; 1988 Mar; 91(1):2-6. PubMed ID: 3371416
[TBL] [Abstract][Full Text] [Related]
15. Criteria for the cure of acromegaly: comparison between basal growth hormone and somatomedin C plasma concentrations in active and non-active acromegalic patients.
Giannella-Neto D; Wajchenberg BL; Mendonça BB; Almeida SF; Macchione M; Spencer EM
J Endocrinol Invest; 1988 Jan; 11(1):57-60. PubMed ID: 3361077
[TBL] [Abstract][Full Text] [Related]
16. Paradoxic elevation in serum GH by hypothalamic releasing hormones predicts GH response to acute SMS 201-995 administration.
Candrina R
Recenti Prog Med; 1991 Jan; 82(1):13-6. PubMed ID: 1902962
[TBL] [Abstract][Full Text] [Related]
17. The GH-releasing hormone (GHRH) test in acromegaly before and after adenomectomy.
Giusti M; Lomeo A; Monachesi M; Mazzocchi G; Attanasio R; Sessarego P; Mignone D; Del Monte P; Giordano G
J Endocrinol Invest; 1987 Apr; 10(2):143-51. PubMed ID: 3108356
[TBL] [Abstract][Full Text] [Related]
18. Effects of growth hormone-releasing factor on growth hormone secretion in acromegaly.
Gelato MC; Merriam GR; Vance ML; Goldman JA; Webb C; Evans WS; Rock J; Oldfield EH; Molitch ME; Rivier J
J Clin Endocrinol Metab; 1985 Feb; 60(2):251-7. PubMed ID: 3917454
[TBL] [Abstract][Full Text] [Related]
19. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
20. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
